A randomised feasibility study of EPA and Cox-2 inhibitor (Celebrex) versus EPA, Cox-2 inhibitor (Celebrex), resistance training followed by ingestion of essential amino acids high in leucine in NSCLC cachectic patients--ACCeRT study.

Files in this item

There are no files associated with this item.

Find Full text

This item appears in the following Collection(s)

Share

Search ResearchSpace


Browse

Statistics